Related Experiment Video
Updated: Jul 13, 2025

12:11
ELIME Enzyme Linked Immuno Magnetic Electrochemical Method for Mycotoxin Detection
Published on: October 23, 2009
14.3K
Efficient Simultaneous Detection of Metabolites Based on Electroenzymatic Assembly Strategy
Anran Zheng1,2, Chao Li1,3, Shengkai Xu4
1CAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China.
BME Frontiers
|October 18, 2023
Summary
A novel electroenzymatic mediator (EM) sensor enables simultaneous detection of three cardiovascular disease (CVD) metabolites in a small plasma sample. This breakthrough offers a more efficient approach to chronic CVD assessment and management.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Cardiovascular Disease Diagnostics
Background:
- Monitoring cardiovascular disease (CVD) metabolites is crucial for assessing disease risk.
- Current hospital-based detection methods are time-consuming and inefficient for chronic CVD management.
Purpose of the Study:
- To develop an electroenzymatic mediator (EM) sensor for simultaneous detection of three key CVD metabolites.
- To improve the efficiency of chronic CVD assessment through a novel sensor technology.
Main Methods:
- An electroenzymatic assembly peak separation strategy was employed.
- Three distinct EM layers were assembled on a single electrode for tunable potential electron transfer.
- Simultaneous quantification of three metabolites was achieved via three distinct peak currents.
Main Results:
- The EM sensor demonstrated high sensitivity for simultaneous detection of three metabolites, with a lower limit of 0.01 mM.
- A strong linear correlation (>0.980) was observed between the sensor and clinical data from 242 patients.
- The risk assessment consistency reached 94.6%.
Conclusions:
- The developed EM sensor is a promising tool for expanding metabolite detection capabilities.
- This sensor technology holds potential as a home healthcare tool for effective CVD risk assessment.

